Vivera Pharmaceuticals Welcomes Gonçalo Leal to Neurosciences Division as Scientific Advisor
NEWPORT BEACH, Calif. – Vivera Pharmaceuticals, Inc., is pleased to welcome Mr. Gonçalo Leal to the Scientific Advisory Board of the Company’s Neurosciences Division. With 15
Vivera Pharmaceuticals Welcomes Shawn Ray to Ambassador Board
NEWPORT BEACH, Calif. – Vivera Pharmaceuticals, Inc., an innovative, science-driven pharmaceutical company, has welcomed Mr. Shawn Ray to the Company’s Ambassador Board. Mr. Ray will not
Vivera Pharmaceuticals Names Dr. Bobby W. Sandage, Jr. to Company’s Board of Advisors
Esteemed pharmaceutical expert joins innovative Newport Beach pharmaceutical companyin pursuit of breakthrough medical developments NEWPORT BEACH, Calif. – Vivera Pharmaceuticals, Inc., an innovative, science-driven pharmaceutical
Vivera Pharmaceuticals Granted Allowance for ZICOH® Patent
NEWPORT BEACH, Calif.– Vivera Pharmaceuticals, Inc. is pleased to announce the allowance of its dose-controlled drug delivery device patent for ZICOH®. Designed to better facilitate
Vivera Pharmaceuticals Welcomes Farah Al Qaissieh as Neurosciences Ambassador
NEWPORT BEACH, Calif.– Vivera Pharmaceuticals, Inc., an innovative, science-driven pharmaceutical company, has named Farah Al Qaissieh to the Ambassador Board of its Neurosciences Division. As
Vivera Attends StutterFEST
Vivera is excited to attend StutterFEST 2021 this Saturday, May 8! Hosted by the World Stuttering Network, StutterFEST is a 20-hour celebration of the stuttering
Investor Relations and Media Inquiries:
Investor Inquiries:
[email protected]
Media Inquiries:
[email protected]
Forward-looking and cautionary statements:
Statements made on our website may contain “forward-looking information” as defined in applicable Canadian securities legislation. All statements other than statements of historical fact included in this release, including, without limitation, future operating margins, future production and processing, processing results, and future plans and objectives of Vivera, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of Vivera and its subsidiaries as a going concern, general economic and market conditions, price of biomass, the accuracy of production resource estimates, and the performance of Vivera’s future operations. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information. Important factors that could cause actual results to differ materially from Vivera’s expectations include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. For additional information with respect to risk factors applicable to Vivera, reference should be made to Vivera’s continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, Vivera’s CSE Listing Statement. The forward-looking information contained on our website is made as of the date of the release of such statement and Vivera does not intend, and expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved or disapproved the contents on our site.
